Stock Events

Stock Events

Neuronetics 

$3.13
46
-$0.02-0.79% 18:07 Today

Statistics

Day High
3.2
Day Low
3.05
52W High
3.71
52W Low
0.8
Volume
18,747
Avg. Volume
-
Mkt Cap
238.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.33
-0.24
-0.14
-0.05
Expected EPS
-0.089667
Actual EPS
N/A

Financials

-26.15%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
149.16MRevenue
-39MNet Income

Analyst Ratings

4.50Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow STIM. It's not an investment recommendation.
Apple
11
AAPL
Microsoft
8
MSFT
Tesla
8
TSLA
Alphabet
8
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Minerva Neurosciences
NERV
Mkt Cap218.68M
Minerva Neurosciences, works on treatments for central nervous system diseases, indirectly competing with Neuronetics' psychiatric focus.
LivaNova
LIVN
Mkt Cap4.53B
LivaNova PLC, a medical device company with products in neuromodulation, directly competes in the neurostimulation market.
Medtronic
MDT
Mkt Cap116.83B
Medtronic, a large diversified medical device company, has a neuromodulation division that competes in the neurostimulation market.

About

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Show more...
CEO
Daniel L. Reuvers
Employees
658
Country
United States
ISIN
US64131A1051
WKN
000A2JPMY

Listings

MU
DE
NRC.MU
STU
DE
NRC.STU
F
DE
NRC.F
XNAS
US
STIM

0 Comments

Share your thoughts

FAQ

What is Neuronetics stock price today?▼
The current price of STIM is $3.13 USD — it has decreased by -0.79% in the past 24 hours. Watch Neuronetics stock price performance more closely on the chart.
What is Neuronetics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Neuronetics stocks are traded under the ticker STIM.
Is Neuronetics stock price growing?▼
STIM stock has fallen by -2.49% compared to the previous week, the month change is a +93.21% rise, over the last year Neuronetics has showed a -7.12% decrease.
What is Neuronetics market cap?▼
Today Neuronetics has the market capitalization of 238.12M
When is the next Neuronetics earnings date?▼
Neuronetics is going to release the next earnings report on November 10, 2026.
What were Neuronetics earnings last quarter?▼
STIM earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.12 USD resulting in a +59.35% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neuronetics revenue for the last year?▼
Neuronetics revenue for the last year amounts to 149.16M USD.
What is Neuronetics net income for the last year?▼
STIM net income for the last year is -39M USD.
How many employees does Neuronetics have?▼
As of August 19, 2026, the company has 658 employees.
In which sector is Neuronetics located?▼
Neuronetics operates in the Health & Wellness sector.
When did Neuronetics complete a stock split?▼
Neuronetics has not had any recent stock splits.
Where is Neuronetics headquartered?▼
Neuronetics is headquartered in MALVERN, United States.